Findings

What do systematic reviews say?

5 questions · 5 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 20%Moderate 4 · 80%High 0 · 0%

Mortality: 10 weeks · HIV‐infected individual with first episode of cryptococcal meningitis

One week of AmBd + 5FC probably leads to lower mortality: 10 weeks compared with two weeks of AmBd + 5FC (moderate certainty).

1 finding from 1 review

Treatment for HIV‐associated cryptococcal meningitis 2018 · Cochrane Headline outcomes only
RR 0.62 [0.42, 0.93]
1 study · 228 participants
Moderate

Mortality: 10 weeks · HIV‐infected individual with first episode of cryptococcal meningitis

One week of AmBd + 5FC probably leads to lower mortality: 10 weeks compared with one week of AmBd + FLU (moderate certainty).

1 finding from 1 review

Treatment for HIV‐associated cryptococcal meningitis 2018 · Cochrane Headline outcomes only
RR 0.49 [0.34, 0.72]
1 study · 224 participants
Moderate

Mortality: 10 weeks · HIV‐infected individual with first episode of cryptococcal meningitis

One week of AmBd + 5FC + FLU showed no clear difference in mortality: 10 weeks compared with one week of AmBd + FLU (low certainty).

1 finding from 1 review

Treatment for HIV‐associated cryptococcal meningitis 2018 · Cochrane Headline outcomes only
RR 0.86 [0.35, 2.1]
1 study · 40 participants
Low

Mortality: 10 weeks · HIV‐infected individual with first episode of cryptococcal meningitis

One week of AmBd + 5FC probably leads to lower mortality: 10 weeks compared with two weeks of AmBd + FLU (moderate certainty).

1 finding from 1 review

Treatment for HIV‐associated cryptococcal meningitis 2018 · Cochrane Headline outcomes only
RR 0.58 [0.39, 0.86]
1 study · 227 participants
Moderate

Mortality: 10 weeks · HIV‐infected individual with first episode of cryptococcal meningitis

One week of AmBd + 5FC probably leads to lower mortality: 10 weeks compared with two weeks of 5FC + FLU (moderate certainty).

1 finding from 1 review

Treatment for HIV‐associated cryptococcal meningitis 2018 · Cochrane Headline outcomes only
RR 0.68 [0.47, 0.99]
1 study · 338 participants
Moderate